Girindus Not Affected by Solvay's Decision to Sell Pharmaceuticals Sector
BERGISCH GLADBACH, Germany & CINCINNATI, Ohio-(Business Wire)-September 29, 2009 - Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its Pharmaceuticals Sector to Abbott. Girindus is a member of Solvay Organics, which is part of the Chemicals Division of the Solvay Group and is therefore completely separate from the Pharmaceuticals Division.
Girindus outstanding knowledge and technical expertise in cGMP manufacturing and process development of oligonucleotides will continue to deliver high quality services to our growing customer base.
Dr. Mark Laskovics, President and Chief Operating Officer of Girindus points out: 'We are fully committed to provide our customers with high-level, sustainable chemistry, analytical and CMC services during the development and manufacture of their oligonucleotide and small molecule medicines now and in the future'.
For further information please contact:
| Markus Georgi |
| Head of Investor Relations |
| Girindus AG, Member of Solvay Organics |
| phone: +49-2204-926-900 |
| Kathryn L. Ackley, Ph.D. |
| Director of Operations |
| Girindus America, Inc, Member of Solvay Organics |
| phone: +1-513-679-3070 |
| Language: | English | |
| Company: | Girindus AG | |
| Buchenallee 20 51427 | ||
| Bergisch Gladbac | ||
| Deutschland | ||
| Phone: | +49 2204 / 926 900 | |
| Fax: | +49 2204 / 926 990 | |
| E-mail: | ||
| Internet: | ||
| ISIN: | DE0005880405 | |
| WKN: | 588040 | |
| Listed: | Regulierter Markt in Frankfurt (General Standard); Freiverkehr in Berlin, München, Düsseldorf, Stuttgart, Hamburg |
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
